Baird Said Road Getting Tougher for Dendreon (DNDN)

Article Stock Quotes (1) Comments (0)

Baird commented on Dendreon (NASDAQ: DNDN) following this weekend's ASCO meeting, saying "Provenge's commercial task has become increasingly difficult with full publication of Zytiga's pre-chemo data at ASCO and the anticipated approval/launch of MDV3100."

The analyst said Dendreon's sequencing message is not resonating, and Zytiga
pre-chemo use is already quite measurable.

"With these two agents dominating mindshare for some time to come, we worry Provenge may increasingly struggle to stay relevant," the firm said.

The firm maintained their Neutral with a new price target of $11.00 (from $13.00).

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $6.76 yesterday, with a 52 week range of $6.46-$42.06.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Brean Capital Raises Onyx (ONXX) Price Target to $115
• Goldman Sachs Upgrades Meritor (MTOR) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?